Cipaglucosidase Alfa
ATC A16AB23 · 5 markets · 6 records
AU 2 records · 2 strengths
- 105 mginjectionPOMBILITI cipaglucosidase alfa 105mg powder for injection vial
Records without a stated strength · 1 POMBILITI
US 1 records · 1 strengths
- 105 mginjectionPOMBILITI ATGA
GB 1 records · 1 strengths
- 105 mginjectionPombiliti 105mg powder for concentrate for solution for infusion vials
CA 1 records · 1 strengths
- 105 mgpowderPOMBILITI
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 POMBILITI
| Strength / form / release | US | GB | CA | AU | EU |
|---|---|---|---|---|---|
| 105 mg injection | POMBILITI ATGA | Pombiliti 105mg powder for concentrate for solution for infusion vials | POMBILITI cipaglucosidase alfa 105mg powder for injection vial | ||
| 105 mg powder | POMBILITI | ||||
unknown | POMBILITI | POMBILITI |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.